 |
| Michael Pellini, CEO of Foundation Medicine |
Foundation Medicine ($FMI) has been on an upward trajectory as of late, inking deals with Big Pharma and expanding the reach for its gene-profiling technology. The company's hard work appears to be paying off, as Foundation's Q4 2014 revenues rose 93% to $18.7 million and oncologists ordered 7,233 of its clinical tests, compared to 3,752 tests ordered during the same quarter last year. Recent milestones, including its collaboration with diagnostics luminary Roche ($RHHBY), will "strengthen all aspects" of the company's business in the coming year, CEO Michael Pellini said in a statement. Statement